Genomics investment in 2017 has already surpassed last year's figure, boosted by the large rounds of funding that diagnostics startups have managed to close. Following the significant advances that have recently been made in the world of diagnostics, the...
M&A advisors with expertise in the technology sector
biotechnology
Latest Sectoral Reports |
Last Entries
The investment fund Columbus Venture Patners and Asklepios will invest up to €9M in the bio sector in Gipuzkoa.
The venture capital fund Columbus and the US company Asklepios set up the joint venture Viralgen to invest in the opening of a viral vector plant in San Sebastian.
Cancer biotechs receive funding: Immunostep and Dp Pharma
In the last month we have heard about two Spanish companies that focus on the fight against cancer, Immunostep and Idp Pharma, which have received funding.
Ysios capital participates in $68M round in Kala pharmaceuticals
Ysios Capital, Spain's leading private equity firm in the biotech sector, announced on 14 April that it has participated in a $68M round in US-based Kala Pharmaceuticals, which specialises in the development of innovative treatments for eye diseases. We review the investments made by this fund manager.
Biotechnology is supported by investors.
Investment in biotechnology is booming. So far this year, in addition to the fact that several biotech companies such as Imbiomotion have received funding, Ysios, Spanish venture capital focused on the health sector, has raised capital for its fund and a new Caixa Impulse call has been opened.
Caixa Capital Risk invests in Inbiomotion
It seems that biotechnology is finding investors in our country. A few weeks ago we told you that Inveready had invested in Cuantum and Ab-biotics, this week we learned that Oncostellae, which received a €1M round is looking for funding, and Caixa Capital Risk has led a €2.2M round in Inbiomotion.
Inveready bets on biotechnology, invests in Cuantum and AB-biotics in less than a month
Inveready has started the year with a strong commitment to biotechnology. A few weeks ago we announced that it had invested in Oncostellae, and recently we have learned that it has invested in two more companies, in Ab-BIOTICS through its debt fund and in Cuantum through its Inveready Biotech II fund.
Oryzon genomics floats on the MAB
Oryzon Genomics is now listed on the MAB, reinforcing the biotech market, which is the largest listed on the MAB. Of the 33 companies listed on the MAB, 8 are active in the biotechnology sector.
France's Synerlab buys Alcalá Pharma
If a week ago we told you that Spanish biotechs were going public on the MAB, this week it is the turn of crowdfunding and acquisitions in the biotech sector.
Spanish biotechs go public
It is not uncommon for the biotech sector to be punished at times in the stock market because of traditional bubbles and high valuations. However, the S&P Biotechnology select Industry index shows that the situation has improved and has risen by 11% since January. Moreover, of the just over 200 biotechs listed on Wall Street, none of them have a sell recommendation. In fact, experts are betting to buy or overweight around 190 of them.
October 2015: Funding for the biotech sector: InnoUp Farma and Oryzon Genomics and Mind The Byte
In the second half of October we have witnessed that two Spanish companies focused on cancer treatment solutions have received funding. In addition, the largest deal in Crowdequity for the biotech sector has also been closed. The protagonist of this operation has been Mind The byte.
Investment analysis of Inveready
Inveready is one of the largest seed capital funds in our country, which was created in 2008, in the midst of the crisis and so far has raised 5 funds worth more than €60M.Inveready is committed to technology-based companies, especially in the field of ICT and biotechnology. Normally its investments range from 200k to 200M.